Clinical Trial Update: This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study evaluating LOU064 for efficacy and safety in chronic spontaneous urticaria inadequately controlled by H1-antihistamines; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• LOU064

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2022-02-16